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Abstract
Background: Glucocorticoid (GC) resistance is frequently seen in acute lymphoblastic leukemia of T-cell lineage
(T-ALL). In this study we investigate the potential and mechanism of using rapamycin to restore the sensitivity of
GC-resistant T-ALL cells to dexamethasone (Dex) treatment.
Methods: Cell proliferation was detected by 3-(4,5-dimethylthiazol-2-yl)- 2,5-diphenyltetrazolium bromide (MTT)
assay. Fluorescence-activated cell sorting (FACS) analysis was used to analyze apoptosis and cell cycles. Western
blot analysis was performed to test the expression of the downstream effector proteins of mammalian target of
rapamycin (mTOR), the cell cycle regulatory proteins, and apoptosis associated proteins.
Results: 10 nM rapamycin markedly increased GC sensitivity in GC-resistant T-ALL cells and this effect was
mediated, at least in part, by inhibition of mTOR signaling pathway. Cell cycle arrest was associated with
modulation of G1-S phase regulators. Both rapamycin and Dex can induce up-regulation of cyclin-dependent
kinase (CDK) inhibitors of p21 and p27 and co-treatment of rapamycin with Dex resulted in a synergistic induction
of their expressions. Rapamycin did not obviously affect the expression of cyclin A, whereas Dex induced cyclin A
expression. Rapamycin prevented Dex-induced expression of cyclin A. Rapamycin had a stronger inhibition of
cyclin D1 expression than Dex. Rapamycin enhanced GC-induced apoptosis and this was not achieved by
modulation of glucocorticoid receptor (GR) expression, but synergistically up-regulation of pro-apoptotic proteins
like caspase-3, Bax, and Bim, and down-regulation of anti-apoptotic protein of Mcl-1.
Conclusion: Our data suggests that rapamycin can effectively reverse GC resistance in T-ALL and this effect is
achieved by inducing cell cycles arrested at G0/G1 phase and activating the intrinsic apoptotic program. Therefore,
combination of mTOR inhibitor rapamycin with GC containing protocol might be an attracting new therapeutic
approach for GC resistant T-ALL patients.
Background
Glucocorticoids (GCs) like prednisolone and dexametha-
sone (Dex) specifically induce apoptosis in malignant
lymphoblasts, and therefore constitute a central role in
the treatment of lymphoid malignancies, particularly
acute lymphoblastic leukemia (ALL) for decades [1].
Reduction of leukemic blasts after GC administration
alone has been observed in 75%-90% of newly diagnosed
ALL in children and initial response to GC therapies
has a strong prognostic value in ALL [2]. High sensitiv-
ity of leukemic blasts to GC determined by in vitro 3-
(4,5-dimethylthiazol-2-yl)- 2,5-diphenyltetrazolium
bromide (MTT) assay was also associated with good
prognosis [3]. However, clinically GC resistance occurs
in 10-30% of untreated ALL patients and is more fre-
quently seen in T-lineage ALL (T-ALL) than B-precur-
sor ALL and GC resistance always leads to the failure of
chemotherapy [4]. T-ALL is a highly malignant tumor
representing 10%-15% of pediatric and 25% of adult
ALL in humans and it is clinically regarded as a high-
risk disease with a relapse rate of about 30% [5,6].
T-ALL has a less favorable prognosis than B-cell ALL.
The mechanisms that underlie the development of GC
resistance are poorly understood and likely vary with
disease type, treatment regimen, and the genetic back-
ground of the patient [7]. However, an increasing num-
ber of reports indicate that activation of mammalian
target of rapamycin (mTOR) signaling pathway may
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contribute to GC resistance in hematological malignan-
cies [8-11]. A recent study, using a database of drug-
associated gene expression profiles to screen for
molecules whose profile overlapped with a gene expres-
sion signature of GC sensitivity/resistance in ALL cells,
demonstrated that the mTOR inhibitor rapamycin pro-
file matched the signature of GC sensitivity [12]. We
recently demonstrated that nucleophosmin-anaplastic
lymphoma kinase (NPM-ALK), an oncogene originated
from t(2;5)(p23;q35) in a subset of non-Hodgkin’s lym-
phoma transformed lymphoid cells to become resistant
to GC or Dex treatment by activating mTOR signaling
pathway and rapamycin could re-sensitize the trans-
formed lymphocytes to Dex treatment [13].
Rapamycin, the best studied mTOR inhibitor, was ori-
ginally isolated from the soil bacterium Streptomyces
hygroscopicus in the mid-1970 s [14]. Although it was
initially developed as a fungicide and immunosuppres-
sant, antitumor activity of rapamycin has been described
in vitro and in vivo [15-18]. mTOR is a serine-threonine
protein kinase that belongs to the phosphoinositide
3-kinase (PI3K)-related kinase family. Inhibition of
mTOR kinase leads to dephosphorylation of its two
major downstream signaling components, p70 S6 kinase
(p70S6K) and eukaryotic initiation factor 4E (eIF4E)
binding protein 1 (4E-BP1), which in turn inhibits the
translation of specific mRNAs involved in cell cycle and
proliferation and leads to G1 growth arrest [19,20]. A
major regulator of the mTOR pathway is the PI3K/AKT
kinase cascade and activation of PI3K/AKT/mTOR has
been found in lymphoid malignancies [21].
Most studies have shown that rapamycin acts as a
cytostatic agent by arresting cells in the G1 phase
[15-20]. Although cell cycle arrest can temporarily halt
tumor progression, the affected clones could re-grow
since the tumor cells have not been killed. Cell cycle
inhibitor seems to work best in combination with che-
motherapy. However, combination of cell cycle inhibitor
with cytotoxic agents might be agonistic or antagonistic
[22,23]. In this paper, we demonstrate that rapamycin
can re-sensitize GC-resistant T-ALL cells to Dex-
induced apoptosis and explore the potential therapeutic




The T-ALL cell lines, Molt-4 (GC resistant) and Jurkat
(GC resistant) were kindly provided by Dr. Stephan W.
Morris (St. Jude Children’s Research Hospital). CEM-C1-
15 (GC resistant) and CEM-C7-14 (GC sensitive) were
kindly provided by Dr. E. Brad Thompson (University of
Texas Medical Branch). All cell lines were maintained in
RPMI 1640 (Gibco, Carlsbad, CA, USA) supplemented
with 10% fetal bovine serum (FBS, Sigma, St Louis, MO,
USA), 2 mM L-glutamine (Gibco), and antibiotics (peni-
cillin 100 U/mL and streptomycin 50 μg/mL) at 37°C in a
humidified 5% CO2 in-air atmosphere.
Reagents and antibodies
Rapamycin (Calbiochem, La Jolla, CA, USA) was dis-
solved in dimethyl sulfoxide (DMSO, Sigma) and used
at the concentration of 10 nM. Dex (Sigma) was dis-
solved in ethanol and used at the concentration of
1 μM. The final concentrations of DMSO and ethanol
in the medium were 0.05% and 0.1%, respectively, at
which cell proliferation/growth or viability was not
obviously altered. MTT and Propidium iodide (PI) were
purchased from Sigma. Annexin V-PI Kit was purchased
from Keygen (Nanjing, China). Antibodies to phospho-
4E-BP1, phospho-p70S6K, cyclin D1, p27, Bax, and
Bcl-2 were purchased from Cell Signaling Technology
(Beverly, MA, USA). Antibody to p21 was purchased
from BD Bioscience (San Jose, CA, USA) and antibodies
to Bim, Mcl-1, cyclin A, caspase-3 (cleaved at Asp175),
NF-B, and secondary antibodies of horseradish peroxi-
dase (HRP)-conjugated donkey anti-rabbit antibody and
HRP-conjugated sheep anti-mouse antibody were all
obtained from Santa Cruz Biotech (Santa Cruz,
CA, USA). Anti-GAPDH antibody was obtained from
Kangchen Bio-Tech (Shanghai, China).
Cell treatment
Logarithmically growing cells were harvested and
replaced in 96- or 6-well sterile plastic culture plates
(Corning Inc., Acton, MA, USA), to which 10 nM rapa-
mycin (Rap group), 1 μM Dex (Dex group), 10 nM rapa-
mycin plus 1 μM Dex (Rap+Dex group), and 0.05%
DMSO plus 0.1% ethanol (Control group) were added
respectively. At the end of the incubation period, cells
were transferred to sterile centrifuge tubes, pelleted by
centrifugation at 400 g at room temperature for 5 min,
and prepared for analysis as described below.
Proliferation assay
MTT assay is based on the conversion of the yellow tet-
razolium salt to purple formazan crystals by metabolically
active cells and provides a quantitative estimate of viable
cells. Cells were seeded in 96-well plates (20,000/mL) and
incubated for 48 h. 0.5 mg/mL MTT (final concentra-
tion) was added to each well for 4 h at 37°C. Then, 100%
(v/v) of a solubilization solution (10% SDS in 0.01 M
HCl) was added to each well, and the plates were re-incu-
bated for 24 h at 37°C. Spectrophotometric absorbance
was measured at 570 nm (reference 690 nm) using a
multi-plate reader (Multiskan Spectrum, Thermo Elec-
tron Co., Vantaa, Finland). Values were obtained by com-
paring these cells with their respective controls.
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Cell cycle analysis
For each analysis, 106 cells were harvested 48 h after
treatment and fixed overnight in 70% ethanol at 4°C.
Cells were then washed and stained with 5 μg/ml PI in
the presence of DNAse free RNAse (Sigma). After 30
min at room temperature, the cells were analyzed via
flow cytometry (Beckman Coulter, Inc., Miami, FL,
USA).
Assay for apoptosis
The samples were washed with phosphate-buffered sal-
ine (PBS) twice and re-suspended in 500 μl of binding
buffer containing 5 μl of Annexin V-FITC stock solution
and 5 μl of PI for determination of phosphatidylserine
exposure on the outer plasma membrane. After incuba-
tion for 10 min at room temperature in a light-protected
area, the samples were quantified by flow cytometry
(FASCAria, BD Bioscience, San Jose, CA).
Western blot analysis
Cells (106) were washed twice in cold PBS, and then
lysed by Laemmli sample buffer (Bio-Rad, Hercules, CA,
USA). Samples were boiled for 5 min at 100°C. Proteins
were separated on 10% or 15% SDS-polyacrylamide gel
electrophoresis (SDS-PAGE) and transferred onto nitro-
cellulose membranes (0.45 μm, Mllipore, São Paulo, SP,
Brazil). Nonspecific-binding sites were blocked with 5%
non-fat dry milk dissolved in TBS (10 mM Tris-HCl,
pH 7.6, 137 mM NaCl) with 0.1% Tween 20 (TTBS) for
1 h at room temperature followed by incubation with
primary antibody at 4°C overnight. The membranes
were then washed 3 times in TTBS and incubated for 1
h at room temperature with secondary horseradish per-
oxidase (HRP)-conjugated donkey anti-rabbit antibody
or HRP-conjugated sheep anti-mouse antibody diluted
1:5000 in TTBS with 5% non-fat milk. Proteins were
visualized by ECL plus (Amersham Biosciences, Inc.,
Piscataway, NJ). All experiments were carried out inde-
pendently at least 3 times. The level of the GAPDH pro-
tein was used as a control of the amount of protein
loaded into each lane.
Statistical analysis
All assays were performed in triplicate, and data are
expressed as mean values ±SD. The Student’s t-test was
used to compare two groups. Results were considered
significant with p-value < 0.05.
Results
Rapamycin and Dex inhibit growth of T-ALL cells
synergistically
It has been reported that rapamycin can sensitize multi-
ple myeloma cells to apoptosis induced by Dex [9,11].
In order to evaluate the potential of rapamycin for the
treatment of GC-resistant ALL, we selected a panel of
four T-ALL cell lines, GC-sensitive CEM-C7-14, and the
GC-resistant CEM-C1-15, Molt-4, and Jurkat. Four cell
lines were incubated for 48 h with rapamycin and/or
Dex. Rapamycin inhibited the growth of all the four
T-ALL cell lines. The percentage of viable cells were
from the lowest of 46% in Molt-4 to the highest of 66%
in CEM-C7-14 as compared to their control group,
p <0.05. The response of the T-ALL cell lines to Dex
varied. The GC-sensitive cell line CEM-C7-14 was
highly sensitive to GC with only 13% of the cells viable.
The other cell lines were GC resistant, with the viability
from the lowest of 69% in Molt-4 to the highest of
112% in Jurkat. However, combination of rapamycin
with Dex strongly enhanced the growth inhibitory effect
on Molt-4, CEM-C1-15, and CEM-C7-14 cells com-
pared with single use of rapamycin or Dex, p < 0.05
(Figure 1A). Although co-treatment of rapamycin with
Dex did not show a stronger growth inhibition com-
pared with singly use of rapamycin at 48 h in Jurkat
cells, there was an obvious difference on the growth
inhibition after 72 h. The cell viability was 45% in the
former versus 31% in the later, p < 0.05 (Figure 1B).
These data suggested that rapamycin and Dex had
synergistic growth inhibition on T-ALL cells.
Rapamycin and Dex acts synergistically on the inhibition
of mTOR signaling pathway
Rapamycin inhibits cell grow through dephosphorylation
of p70S6K and 4E-BP1 [15-20]. The phosphorylation
status of p70S6K and 4E-BP1 is commonly employed to
assess the inhibition of mTOR by rapamycin. We per-
formed Western blot analysis using antibodies specific
for the p70S6K phosphorylation sites Thr421/Ser424
and 4E-BP1 phosphorylation sites Thr37/46 in Molt-4
cells. Just as expected, rapamycin inhibited phosphoryla-
tion of both p70S6K and 4E-BP1 (p-p70S6K and p-4E-
BP1). Dex alone had no effect on p-p70S6K and p-4E-
BP1. However, when combined use of these two drugs,
a synergistic inhibition of mTOR signaling was detected
by de-phosphorylation of p70S6K and 4E-BP1 (Figure
2). These results suggested that inhibition of the mTOR
signaling pathway may potentiate the cytotoxic effect of
Dex. The same results were obtained in both Jurkat and
CEM-C1-15 cells (data not shown).
Rapamycin and Dex arrest T-ALL cells in G0/G1 phase of
the cell cycle
The main role of rapamycin is to induce cell cycle arrest
[19,20]. Flow cytometric analysis showed that 48 h treat-
ment with rapamycin clearly induced G0/G1 arrest in all
4 cell lines of T-ALL. In GC-sensitive cell line, CEM-
C7-14, Dex itself, can induce G0/G1 arrest, and co-treat-
ment with rapamycin increased the G0/G1 phase slightly,
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from 67% to 70%, p > 0.05. But in GC-resistant cell
lines, rapamycin augmented the effect of G0/G1 arrest
significantly, from 45% to 58% in CEM-C1-15 cells, 50%
to 65% in Jurkat cells, and 57% to 75% in Molt-4 cells,
p < 0.05 (Figure 3A).
To evaluate the molecular basis underlying cell cycle
arrest, we investigated the expression of cell cycle regu-
latory proteins. As shown in Figure 3B, both rapamycin
and Dex could induce up-regulation of cyclin-depen-
dent kinase (CDK) inhibitors of p21 and p27, and a
Figure 1 Rapamycin augments Dex’s growth inhibition on T-ALL cell lines. (A) Four T-ALL cell lines (CEM-C7-14, CEM-C1-15, Molt-4, and
Jurkat) were incubated for 48 h with rapamycin (10 nM) and/or Dex (1 μM), and the proliferation rate of the cells were evaluated by MTT assay.
(B) GC-resistant cell line Jurkat was exposed for 72 h to rapamycin (10 nM) and Dex (1 μM) alone or in combination. At time 0, 24, 48 and 72 h
after treatment, proliferation rate of the cells were evaluated by MTT assay. For each assay, values of triple experiments were shown as mean
plus or minus SD. * p < 0.05 as compared with control group or Rap group or Dex group.
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synergistic effect of induction was detected when using
these two drugs together. Rapamycin did not obviously
affect the expression of cyclin A, whereas dexametha-
sone induced cyclin A expession. Rapamycin prevented
dexamethasone-induced expression of cyclin A. Cyclin
D1 levels were reduced when treated with rapamycin or
dexamethasone alone, or in combination. Compared
with Dex, rapamycin had a stronger effect on down-reg-
ulation of cyclin D1.
Rapamycin sensitizes T-ALL cells to Dex-induced
apoptosis
Cell cycle arrest could not explain the magic effect on
growth inhibition of Dex when co-treated with rapamy-
cin. The main mechanism of Dex in the treatment of
lymphoid malignancies is to induce apoptotic cell death.
We used Annexin V-PI staining to determine the early
stage of apoptosis. Dex, used alone at 1 μM (Dex
group), had no apoptotic effect on Jurkat and Molt-4
cells, and there was only a minimal effect on CEM-C1-
15 cells at 48 h and a modest effect on CEM-C7-14
cells at 24 h (After 24 h the cells came to the late phase
of apoptosis, data not shown.), p >0.05. Rapamycin, used
at 10 nM (Rap group), also had no obvious apoptosis-
inducing effect on all 4 cell lines, although at this con-
centration, significant cell cycle arrest at G1 phase
occurred (Figure 3A). However, when combined Dex
with rapamycin (Rap+Dex group), a remarkable increase
in cell apoptosis was ensued in all 4 cell lines (Figure
4A). Compared with Rap group, the combination treat-
ment group of cells increased the apoptotic rate from
3% to 20% in CEM-C7-14 at 24 h, p <0.05, from 3%
to 16% in CEM-C1-15 cells at 24 h, p <0.05, from 9% to
18% in Jurkat cells at 72 h, p <0.05, and from 5% to
14% in Molt-4 cells at 48 h, p <0.05. Taken together,
these results suggest that rapamycin can augment the
cytotoxic effect of Dex in both GC-sensitive and resis-
tant cells.
The ability to up-regulate glucocorticoid receptor (GR)
expression upon GC exposure has been demonstrated in
various cell lines of lymphoid leukemias and this up-reg-
ulation of GR has been suggested as an essential step to
the induction of apoptosis in leukemic cells [24]. In
Molt-4 cells, we found no change of GR expression after
treatment with rapamycin or Dex singly or in combina-
tion (Figure 4B). So up-regulation of GR expression
might not participate in the mechanism of rapamycin’s
reversion of GC resistance in GC-resistant T-ALLs. In
the same cells, we found that although caspase-3 was
not activated by rapamycin or Dex alone, but a strong
activation was ensued after combined treatment (Figure
4B), suggesting that apoptosis mechanism did involve in
the process. We then examined the expressions of Bcl-2,
Bax, Bim-EL, and Mcl-1 in Molt-4 cells. Similar to other
study [12], levels of the anti-apoptotic protein Bcl-2 was
unchanged after exposure to rapamycin or Dex alone or
in combination, whereas Mcl-1 level was reduced signif-
icantly after exposure to rapamycin alone or in combi-
nation with Dex, but not modulated by Dex alone. Both
Dex and rapamycin induced expression of Bim-EL and
Bax significantly and there was a synergistic effect when
they were used together (Figure 5). These data further
support that rapamycin reverses GC resistance via acti-
vation of the intrinsic apoptotic program.
Disccusion
In vivo response to 7 days of monotherapy with predni-
sone is a strong and independent prognostic factor in
Figure 2 The effect of rapamycin and Dex on mTOR pathway. Molt-4 cells were treated with rapamycin and/or Dex. After 48 h, cells were
lysed and followed by Western blot analysis using antibodies specific for the p70S6K phosphorylation sites Thr421/Ser424 and 4E-BP1
phosphorylation sites Thr37/46.
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childhood ALL [25]. Despite intensive research efforts,
GC resistance remains a major obstacle to successful T-
ALL treatment. Increasing evidences now indicate that
rapamycin, the mTOR inhibitor, could be used as a
potential GC sensitizer [9-13]. In this study, we wanted
to explore the possibility of using rapamycin as a
therapeutic element in the GC-resistant T-ALLs. Our
results showed that Dex had minimal effects on the cell
growth and apoptosis of the GC-resistant T-ALL cell
lines, but when it was used to co-treat the cells with
rapamycin, a stronger growth inhibitory and apoptosis-
inducing effect was achieved and it was done through
Figure 3 The effect of rapamycin and Dex on cell cycles and the cell cycle regulatory proteins. (A) T-ALL cells were incubated for 48 h
with rapamycin(10 nM) and/or Dex (1 μM) and the cell cycle phases were analyzed by PI staining. For all experiments, values of triple
experiments were shown as mean plus or minus SD. * p < 0.05 as compared with control group or Dex group or Rap group except for CEM-C1-
15 cells. (B) Cell-cycle proteins were studied. After 48 h exposure to rapamycin and/or Dex, Molt-4 cells were lysed and extracts were analyzed
by Western blotting. R, rapamycin; D, Dex; RD, rapamycin+Dex; and C, control.
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synergistically inhibiting mTOR signaling, suggesting a
rationale of adding mTOR inhibitor in the treatment of
GC resistant T-ALLs in clinics.
Down-regulation of cyclin D1 along with up-regula-
tion of CDK inhibitors p21 and p27 have previously
been suggested to be the mechanism behind mTOR
inhibitor induced cell cycle arrest [26,27]. We got the
same results in GC-resistant Molt-4 cells. We also
found that compared with rapamycin treatment alone,
combined treatment with Dex decreased the expression
level of cyclin A, which would also contribute to the
effect of cell cycle arrest at G1 phase.
Figure 4 Rapamycin sensitizes T-ALL cells to GC treatment by enhancing apoptotic cell death. (A) T-ALL cells were incubated for 24~72 h
(according to different time points to early stage of apoptosis) with rapamycin(10 nM) and/or Dex (1 μM), and the early stage of apoptosis were
detected by Annexin V-FITC/PI staining. For all experiments, values of triple experiments were shown as mean plus or minus SD. * p < 0.05 as
compared with control group or Dex group or Rap group (except for Jurkat cells at 48 h). (B) After 48 h exposure to rapamycin and/or Dex,
Molt-4 cells were lysed and extracts were analyzed by Western blotting for GR expression.
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It’s an exciting finding that rapamycin can reverse GC
resistance in T-ALL cell lines, although the exact mechan-
ism of GC resistance has poorly understood yet. GC resis-
tance may caused by lack of GR up-regulation upon GC
exposure in leukemia cell lines [28]. However, evidence
showed that GC resistance in childhood ALL cannot be
attributed to an inability of resistant cells to up-regulate
the expression of the GR upon GC exposure, nor to differ-
ences in GR promoter usage [24]. Our studies demon-
strated that rapamycin’s reversion of GC resistance in T-
ALLs was not through modulation of GR expression.
Bcl-2 family members are critical regulators of the
intrinsic apoptotic pathway and play critical roles in
GC-induced apoptosis [29]. The members of this family
can be divided into two groups, the anti-apoptotic pro-
teins, such as Bcl-2 and Mcl-1, and the pro-apoptotic
proteins, such as Bax and Bim. The down-regulation of
Mcl-1 was recently shown to be critical for sensitizing
GC-induced apoptosis in lymphoid malignancy cells
[12]. Our studies showed that in Molt-4 cells rapamycin
can inhibit Mcl-1 and rapamycin and Dex have a syner-
gistic induction of Bax and Bim, suggesting that rapamy-
cin sensitizes GC-induced apoptosis in T-ALL cells by
modulation of apoptosis related proteins.
In conclusion, we show in this study that rapamycin
enhances Dex induced apoptosis by inhibition of mTOR
signaling pathway and activation of the intrinsic apoptotic
program. Clinical trials of rapamycin and its derivates have
been completed or are ongoing for the treatment of hema-
tologic malignancies [21]. Therefore, combination of these
drugs with current ALL protocols might be an attracting
new therapeutic approach for GC-resistant T-ALL patients.
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